We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+10.35%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$113M
AUM Growth
-$2.14M
(-1.9%)
Cap. Flow
-$5.51M
Cap. Flow
% of AUM
-4.87%
Top 10 Holdings %
Top 10 Hldgs %
14.17%
Holding
280
New
34
Increased
61
Reduced
100
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Financials Index ETF
FNCL
|
+$1.46M |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.13M |
| 3 |
MediciNova
MNOV
|
+$969K |
| 4 |
ADVM
Adverum Biotechnologies
ADVM
|
+$866K |
| 5 |
CLSD
Clearside Biomedical
CLSD
|
+$856K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Information Technology Index ETF
FTEC
|
+$2.78M |
| 2 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$1.32M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$1.22M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$1.01M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$938K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.9% |
| 2 | Financials | 0.8% |
| 3 | Technology | 0.58% |
| 4 | Consumer Discretionary | 0.4% |
| 5 | Energy | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares 20+ Year Treasury Bond ETF
TLT
$42.5B
| $4.46M | 3.95% |
36,665
+9,465
| +35% | +$1.13M |
|
|
VPU
2
Vanguard Utilities ETF
VPU
$8.62B
| $2.38M | 2.11% |
20,545
-2,300
| -10% | -$258K |
|
|
3
Fidelity MSCI Financials Index ETF
FNCL
$2.35B
| $1.41M | 1.24% |
+35,927
| New | +$1.46M |
|
4
Vanguard Energy ETF
VDE
$9.84B
| $1.39M | 1.23% |
13,206
+1,808
| +16% | +$185K |
|
5
iShares MSCI India ETF
INDA
$6.81B
| $1.24M | 1.09% |
37,169
+767
| +2% | +$26K |
|
|
XLRN
6
DELISTED
Acceleron Pharma
XLRN
| $1.09M | 0.96% |
22,469
+1,648
| +8% | +$60K |
|
7
Vanguard Real Estate ETF
VNQ
$39.4B
| $1.05M | 0.93% |
12,955
+19
| +0.1% | +$1.47K |
|
8
Regenxbio
RGNX
$558M
| $1.04M | 0.92% |
14,492
-12,068
| -45% | -$576K |
|
9
Verastem
VSTM
$513M
| $985K | 0.87% |
+11,932
| New | +$730K |
|
10
Sarepta Therapeutics
SRPT
$1.81B
| $977K | 0.86% |
7,391
-9,018
| -55% | -$850K |
|
11
Arrowhead Research
ARWR
$10.3B
| $933K | 0.82% |
+68,587
| New | +$641K |
|
|
TVRD
12
Tvardi Therapeutics
TVRD
$26.3M
| $927K | 0.82% |
1,345
-304
| -18% | -$155K |
|
13
Cartesian Therapeutics
RNAC
$237M
| $884K | 0.78% |
+2,223
| New | +$789K |
|
|
ALBO
14
DELISTED
Albireo Pharma Inc
ALBO
| $876K | 0.77% |
+24,688
| New | +$800K |
|
15
uniQure
QURE
$2.8B
| $872K | 0.77% |
23,063
-19,441
| -46% | -$623K |
|
|
KYNB
16
Kyntra Bio
KYNB
$29.3M
| $860K | 0.76% |
549
-181
| -25% | -$236K |
|
|
ATNX
17
DELISTED
Athenex, Inc. Common Stock
ATNX
| $846K | 0.75% |
2,266
+36
| +2% | +$12.3K |
|
|
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
| $841K | 0.74% |
+63,829
| New | +$763K |
|
|
CBAY
19
DELISTED
Cymabay Therapeutics
CBAY
| $831K | 0.73% |
61,951
-31,366
| -34% | -$393K |
|
|
MYOK
20
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $823K | 0.73% |
16,580
-3,022
| -15% | -$146K |
|
21
BioCryst Pharmaceuticals
BCRX
$2.34B
| $820K | 0.73% |
143,132
-11,015
| -7% | -$60.6K |
|
22
Abeona Therapeutics
ABEO
$373M
| $817K | 0.72% |
2,042
+156
| +8% | +$68.2K |
|
|
CLSD
23
DELISTED
Clearside Biomedical
CLSD
| $814K | 0.72% |
+5,078
| New | +$856K |
|
|
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $810K | 0.72% |
16,429
-26,707
| -62% | -$1.01M |
|
25
Vertex Pharmaceuticals
VRTX
$123B
| $801K | 0.71% |
4,711
-1,623
| -26% | -$252K |
|
Similar funds
AMIM
EFS
NCM
OC
LIWM
VFG
IAM
1M
Virtus ETF Advisers's Q2 2018 Portfolio in Review
As of Q2 2018, Virtus ETF Advisers held 280 positions worth $113M, down 1.9% from $115M the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Virtus ETF Advisers withdrew a net $5.51M in Q2 2018, closing 19 positions and reducing 100 holdings. Its most notable exit was Jounce Therapeutics, Inc. Common Stock, an estimated $1.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 79% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in Fidelity MSCI Financials Index ETF worth $1.41M.
- Virtus ETF Advisers's largest Q2 2018 buy was Fidelity MSCI Financials Index ETF: 35,927 shares worth $1.41M.
- Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q2 2018, an estimated $1.13M increase.
- Virtus ETF Advisers's biggest Q2 2018 reduction was Fidelity MSCI Information Technology Index ETF, cutting an estimated $2.78M.
- Virtus ETF Advisers fully exited Jounce Therapeutics, Inc. Common Stock in Q2 2018, selling an estimated $1.32M.
- Virtus ETF Advisers's ten largest holdings make up 14% of its $113M portfolio in Q2 2018.
- Virtus ETF Advisers opened 34 new positions and closed 19 in Q2 2018.
- Virtus ETF Advisers's portfolio value fell 1.9% quarter-over-quarter to $113M.
Based on Virtus ETF Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.